Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
The potential promise of therapeutic vaccination as effective therapy for hematologic malignancies is supported by the observation that allogeneic hematopoietic cell transplantation is curative for a subset of patients due to the graft-versus-tumor effect mediated by alloreactive lymphocytes. Tumor vaccines are being explored as a therapeutic strategy to re-educate host immunity to recognize and target malignant cells through the activation and expansion of effector cell populations. Via several mechanisms, tumor cells induce T cell dysfunction and senescence, amplifying and maintaining tumor cell immunosuppressive effects, resulting in failure of clinical trials of tumor vaccines and adoptive T cell therapies.
Source: Blood Reviews - Category: Hematology Authors: Myrna R. Nahas, Jacalyn Rosenblatt, Hillard M. Lazarus, David Avigan Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Education | Hematology | Transplants | Vaccines